Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the Euro
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that target
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) a
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
06:55pm, Thursday, 07'th May 2026
Celldex Therapeutics (CLDX) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $0.81 per share a year ago.
Celldex Reports First Quarter Financial Results and Provides Corporate Update
04:01pm, Thursday, 07'th May 2026
HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.
Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial
08:55am, Thursday, 07'th May 2026
Celldex is positioned as a platform immunology company, leveraging barzolvolimab's mast-cell depletion mechanism beyond chronic urticaria. CLDX's robust cash position ($518.6M at 2025 year-end, $345M
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
10:56am, Monday, 04'th May 2026
The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment
03:35am, Wednesday, 15'th Apr 2026
Celldex Therapeutics (NASDAQ: CLDX) executives used an appearance at H.C. Wainwright's annual Inflammation and Skin Disease Conference to highlight the company's late-stage plans for barzolvolimab, an
Celldex to Present at Upcoming Investor Conference
04:01pm, Monday, 13'th Apr 2026
HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Vi
SG Americas Securities LLC Has $1.29 Million Holdings in Celldex Therapeutics, Inc. $CLDX
04:46am, Wednesday, 08'th Apr 2026
SG Americas Securities LLC grew its position in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 143.2% during the fourth quarter, according to the company in its most recent disclosure with the Securitie
HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten pu
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
09:48pm, Wednesday, 01'st Apr 2026
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,34
Celldex Announces Proposed Public Offering of Common Stock
04:01pm, Wednesday, 01'st Apr 2026
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering f
- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life - - Data further d emonstrates first-in-class and best-in-disease barzolvolimab profile -
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages
02:22am, Monday, 23'rd Mar 2026
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the firm, MarketBeat report
